跳转至内容
Merck
  • Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection.

Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection.

Emerging infectious diseases (2018-01-20)
Tim R H Read, Jørgen S Jensen, Christopher K Fairley, Mieken Grant, Jennifer A Danielewski, Jenny Su, Gerald L Murray, Eric P F Chow, Karen Worthington, Suzanne M Garland, Sepehr N Tabrizi, Catriona S Bradshaw
摘要

High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.

材料
货号
品牌
产品描述

Sigma-Aldrich
Pristinamycin, ≥98% (Assay)
SKU
包装规格
是否有货
价格
数量